News & Updates

New drug applications approved by US FDA as of 1-15 September 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Sacubitril/valsartan appears to be safe and beneficial in the treatment of children with heart failure (HF) attributable to systemic left ventricular systolic dysfunction (LVSD), with the drug having comparable efficacy as enalapril, according to the 52-week data from the phase 2/3 PANORAMA-HF* trial.

Some childhood cancer survivors (CCS) may experience psychological distress and have low health-related quality of life (HRQOL) after completing their cancer treatments, suggests a Singapore study.

Prediabetes in adolescent or young adult females has been linked to increased likelihood of gestational diabetes and adverse maternal and neonatal outcomes at first birth in a recent retrospective cohort study.

Children who have a history of firearm injury remain at increased risk for encountering another firearm injury, reports a US study.